Palvella Therapeutics (PVLA) Asset Utilization Ratio (2014 - 2024)
Palvella Therapeutics (PVLA) reported Asset Utilization Ratio of 0.69 for Q3 2024, up 33.17% year-over-year from 0.51 in Q4 2023, and down 47.59% on a QoQ basis from 1.31 in Q2 2024.
Palvella Therapeutics (PVLA) has 11 years of Asset Utilization Ratio data on file, last reported at 0.69 in Q3 2024.
- Quarterly Asset Utilization Ratio rose 33.17% year-over-year to 0.69 in Q3 2024, while the trailing twelve-month figure through Sep 2024 was 0.69 (up 33.17% YoY) and the FY2021 annual result came in at 0.22, down 9.31% from the prior year.
- Asset Utilization Ratio declined to 0.69 in Q3 2024 per PVLA's latest filing, from 1.31 in the prior quarter.
- Across five years, Asset Utilization Ratio topped out at 2.03 in Q1 2024 and bottomed at 0.13 in Q3 2021.
- The 5-year median for Asset Utilization Ratio is 0.26 (2021), against an average of 0.43.
- The widest annual swing landed in 2021, when Asset Utilization Ratio tumbled 57.47%; it then surged 983.92% in 2024.
- Tracing PVLA's Asset Utilization Ratio over 5 years: stood at 0.27 in 2020, then sank by 44.83% to 0.15 in 2021, then grew by 25.78% to 0.18 in 2022, then soared by 179.23% to 0.51 in 2023, then jumped by 33.17% to 0.69 in 2024.
- Per Business Quant, the three latest PVLA Asset Utilization Ratio figures stand at 0.69 (Q3 2024), 1.31 (Q2 2024), and 2.03 (Q1 2024).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 0.60 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 0.47 |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 0.29 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 0.37 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 0.85 |
| 10 | Palvella Therapeutics | 1.47 Bn | 1.21 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 0.69 |
| Jun 30, 2024 | 1.31 |
| Mar 31, 2024 | 2.03 |
| Sep 30, 2023 | 0.51 |
| Jun 30, 2023 | 0.30 |
| Mar 31, 2023 | 0.19 |
| Sep 30, 2022 | 0.18 |
| Jun 30, 2022 | 0.18 |
| Mar 31, 2022 | 0.15 |
| Dec 31, 2021 | 0.15 |
| Sep 30, 2021 | 0.13 |
| Jun 30, 2021 | 0.15 |
| Mar 31, 2021 | 0.26 |
| Dec 31, 2020 | 0.27 |
| Sep 30, 2020 | 0.26 |
| Jun 30, 2020 | 0.35 |
| Mar 31, 2020 | 0.28 |
| Dec 31, 2019 | 0.25 |
| Sep 30, 2019 | 0.24 |
| Jun 30, 2019 | 0.17 |
| Mar 31, 2019 | 0.21 |
| Dec 31, 2018 | 0.17 |
| Sep 30, 2018 | 0.27 |
| Jun 30, 2018 | 0.23 |
| Mar 31, 2018 | 0.20 |
| Dec 31, 2017 | 0.25 |
| Sep 30, 2017 | 0.10 |
| Jun 30, 2017 | 0.08 |
| Mar 31, 2017 | 0.12 |
| Dec 31, 2016 | 0.15 |
| Sep 30, 2016 | 0.06 |
| Jun 30, 2016 | 0.06 |
| Mar 31, 2016 | 0.04 |
| Dec 31, 2015 | 0.01 |
| Sep 30, 2015 | 0.03 |
| Jun 30, 2015 | 0.07 |
| Mar 31, 2015 | 0.05 |
| Sep 30, 2014 | 126.25 |
| Jun 30, 2014 | 123.21 |